sJIA and AOSD share the same features, and the same four major symptoms. However, the two conditions have traditionally been separated by a person’s age at diagnosis.
Lilly, Novo’s bet on heart disease starts to take shape, and 2024 could be a pivotal year for their GLP-1s
Eli Lilly and Novo Nordisk are steadily — and somewhat quietly — preparing to build comprehensive cardiovascular franchises helmed by their lucrative treatments for diabetes